New financing round for dry eye portfolio

Article

Novaliq has secured €13.9 million in a fifth round of financing for a dry eye portfolio.

Novaliq has secured €13.9 million in a fifth round of financing for a dry eye portfolio.

Exclusive financing was obtained from Dievini Hopp, an active investor in life and health sciences. The funds will be used to progress the pharmaceutical project CyclASol into clinical development. Since 2007 the firm has raised €27.1 million for the dry eye treatment portfolio.

Dievini Hopp Managing Director, Mathias Hothum, stated, "Novaliq is an entirely new class of topical drugs for ophthalmic indications, including dry eye, which have the capability to offer compelling alternatives to current products. We are delighted to invest further in Novaliq, with its pioneering ocular drug delivery technology and strong management team."

Bernhard Günther, CEO of Novaliq, commented, "We are pleased about the ongoing confidence and support from our investor in order to systematically develop the company with our technology platform. Our leading prescription product, CyclASol, is the first Cyclosporine A solution for dry eye disease, while other products are based on emulsions, containing potentially irritating surfactants."

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.